Medical Companies

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Pure Protein is a biopharmaceutical company specializing in immunology tools for diagnostics, drug and vaccine development, and high-yield protein production. Our proprietary soluble HLA (sHLA) production method generates pure, single species antigens with increased yield and correct processing, enabling powerful insight into the workings of diseased cells. In addition, we offer expert HLA proteomics services, and our partner Mimotopes, Inc. ( www.pureproteinllc.com )

Pure Protein LLC
800 Research Parkway Suite 414
Oklahoma City, Oklahoma 73104
USA

Tel: (512) 263-3232
Fax: (405) 271-3848

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Zetiq offers the first ever tool capable of transforming the non-toxic cancer drug revolution into a reality. Non-toxic anti-cancer drugs commonly labeled cancer-regulating agents, are widely expected to replace most cytotoxic agents presently in use. By offering the only high throughput solution capable of screening large chemical libraries for these types of agents as well as performing large-scale target validations Zetiq’s technology will play a unique enabling role within this new therapeutic paradigm. ( www.zetiq.com )

Zetiq Technologies Ltd
1774 Indian Run Road
Malvern, Pennsylvania 19355
USA

Tel: (610) 408-2090
Fax: (610) 408-2091

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Established in 2004, ODC Therapy Inc. is a privately held company focused on the development and commercialization of active (vaccine) and passive (monoclonal antibody) immunotherapies for cancer. ODC has licensed a portfolio of intellectual property from Baylor Research Institute and Rockefeller University and has the option to license additional developments in cancer immunotherapy from Baylor Research Institute. Presently, ODC is seeking to raise capital through a Series A preferred offering. The Company’s cancer vaccines are produced by removing dendritic cell precursors from a patient’s bloodstream, culturing and loading the cells with tumor antigens and then reintroducing them back into the same ( www.odctherapy.com )

ODC Therapy , Inc.
3310 Live Oak Street Suite 401
Dallas, Texas 75204
USA

Tel: (214) 826-7019

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Cognitive Pharmaceuticals was established in 2001 based on a proprietary platform technology developed at the University of Toledo, College of Pharmacy, and in April 2003 was registered in Michigan as a for-profit organization [www.medc.michigan.org] [www.michbio.org]. Emphasis is on products with significant return on investment in expanding markets with unmet needs. A potential treatment of Alzheimer’s disease is presently in development. The mechanism of action of CDD-0102 differs from marketed drugs, targeting both the symptoms – progressive loss of memory and cognitive function – and the underlying cause of the disease – accumulation of amyloid plaque and neurofibrillary ( www.cognitivepharma.com )

Cognitive Pharmaceuticals , Ltd.
6722 Spring Creek Lane
Plymouth, Michigan 48170
USA

Tel: (248) 437-5129
Fax: (248) 437-7656

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
NovaCal Pharmaceuticals is a clinical-stage pharmaceutical company developing a new class of compounds: The AganocideÔ compounds. They are novel, safe and effective non-antibiotic antimicrobial molecules. Our goals are two-fold: 1) to reduce the threat of hospital-based infections, and 2) to provide better treatments for conditions where current therapies are not effective. The AganocideÔ compounds are direct-acting products that can prevent and treat serious bacterial, fungal and viral infections. NovaCal’s antimicrobial products are patterned after small molecule chemicals that white blood cells naturally produce to kill ( www.novacal.com )

NovaCal Pharmaceuticals , Inc.
5980 Horton Street Suite 550
Emeryville, California 94608
USA

Tel: (510) 595-1100
Fax: (510) 291-8811

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
AnGes MG has already been clinically developing the use of HGF gene for ischemic heart disease (IHD) in the U.S. This patent strongly supports the further application of HGF gene for other new heart diseases. In addition to the U.S., AnGes MG has filed patent applications for the present invention in Asian countries including Japan, and European countries. AnGes MG has globally filed patent applications with targets such as Parkinson’s disease, dermatosis and hearing impairment in addition to the abovementioned current clinical development and is making efforts to establish related intellectual property rights. ( www.anges-mg.com )

AnGes MG , Inc.
12707 High Bluff Drive Suite 200
San Diego, California 92130
USA

Tel: (858) 350-4242
Fax: (858) 794-1450

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
AriaVax, Inc. is a research stage biotechnology company that develops novel vaccines for a variety of diseases. AriaVax vaccines are based on its proprietary peptide chemistry technology exclusively licensed by the Company from The National Institutes of Health. This technology allows the development of vaccines that selectively and specifically generate effective antibody-inducing immune responses against previously inaccessible critical segments of viral or bacterial proteins, or the cellular proteins to which these pathogens attach. ( www.ariavax.com )

AriaVax , Inc.
15200 Shady Grove Road Suite 202
Gaithersburg, Maryland 20850
USA

Tel: (301) 296-4234
Fax: (301) 296-4350

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Osteologix is developing novel compounds intended to treat osteoporosis and other bone diseases. The lead compound, NBS-101, is a proprietary strontium-based compound and is part of a class of compounds with a new mechanism of action compared to products currently marketed in the U.S. In 2004 total sales of products to treat osteoporosis were $5.4 billion in the U.S., while worldwide sales were estimated to be $12 billion. Osteologix was founded in Copenhagen, Denmark and is headquartered in San Francisco, and has operations at both sites. It has been financed solely by Nordic Biotech, a venture capital firm headquartered in Copenhagen, Denmark. In October 2004 the Company appointed Charles J. Casamento to CEO and President. Osteologix is Mr. Casamento’s fourth biotech startup. ( www.osteologix.com )

Osteologix, Inc.
425 Market Street Suite 2230
San Francisco, California 94105
USA

Tel: (415) 955-2726
Fax: (415) 955-2727